bearish
Burning Rock Biotech (BNR US): Attractive Growth Story Outshined by Surging COVID Cases in China
364 Views31 Mar 2022 17:44
SUMMARY
- Burning Rock Biotech (BNR US) shares plunged 35% since I published bearish insight on the company in November. Weak Q3 results, slower recovery, and the U.S.-China conflict remained major overhangs.
- However, the shares are now trading at two-week high, as the company received approval for its second NGS kit in China and reported slightly better-than-expected Q4 results.
- Investors should continue to avoid Burning Rock shares for near-term and wait for COVID cases to subside in China and resolution of the U.S.-China conflict.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
- Burning Rock Biotech (BNR US): Despite Q2 Results Missing Consensus Management Reiterated Guidance01 Sep 2022
- Burning Rock Biotech (BNR US) 1Q22: Double-Digit Revenue Growth; China Re-Opening to Boost Recovery02 Jun 2022
- Burning Rock Biotech (BNR US): Attractive Growth Story Outshined by Surging COVID Cases in China31 Mar 2022
- Burning Rock Biotech (BNR US): Muted Near-Term Outlook on Resurgence of COVID-19 in China07 Nov 2021
- Burning Rock (燃石医学) IPO Trading: Hot Deal, Small Float12 Jun 2020
x